• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt

tetano

Editor, Senior Moderator
Poult Sci. 2019 Jul 2. pii: pez385. doi: 10.3382/ps/pez385. [Epub ahead of print]
[h=1]Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt.[/h] Gomaa MR[SUP]1[/SUP], Khalil AA[SUP]2[/SUP], Kandeil A[SUP]1[/SUP], Sabir JSM[SUP]3,[/SUP][SUP]4[/SUP], Kayed A[SUP]1[/SUP], Moatasim Y[SUP]1[/SUP], El Saied MF[SUP]5[/SUP], El-Safty MM[SUP]5[/SUP], Kayali G[SUP]6,[/SUP][SUP]7[/SUP], Ali MA[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Low pathogenicity avian influenza (LPAI) H9N2, highly pathogenic avian influenza (HPAI) H5N1, and H5N8 circulate in Egyptian poultry and cause veterinary and public health burdens. In response, AIV vaccines are commonly used. The main objective of this study was to develop a broad, cross-protective, trivalent vaccine based on circulating AIVs in Egypt. We generated highly replicating avirulent AIVs, H5N1, and H5N8, to be used in combination with H9N2 strain for the generation of an inactivated vaccine. Immunogenicity and protective efficacy of this vaccine were tested. Results showed that a single immunization dose enhanced humoral immune responses giving full protection against challenges with LPAI H9N2, HPAI H5N1, and H5N8 viruses. This efficacious vaccine will reduce the cost of vaccination for poultry growers and is expected to be effective in the field as it is based on contemporary viruses currently in circulation among Egyptian poultry.
? 2019 Poultry Science Association Inc.


[h=4]KEYWORDS:[/h] Egypt; avian influenza; trivalent; vaccine

PMID: 31265106 DOI: 10.3382/ps/pez385
 
Back
Top Bottom